Alimam, Samah
https://orcid.org/0000-0003-4784-7324
Mayo Clinic
Guy's and St Thomas' NHS Foundation Trust
Citations 1
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Harrison, Claire , Mead, Adam J. , Panchal, Anesh, Fox, Sonia, Yap, Christina , Gbandi, Emmanouela, Houlton, Aimee E., Alimam, Samah , Ewing, Joanne, Wood, Marion , Chen, Frederick , Coppell, Jason, Panoskaltsis, Nicki , Knapper, Steven , Ali, Sahra, Hamblin, Angela , Scherber, Robyn M. , Dueck, Amylou C. , Jackson, Aimee , Scherber, Robyn, Mesa, Ruben, Dueck, A. C. , Mead, Adam J , Cross, Nicholas C.P. , Mesa, Ruben A. , McMullin, Mary Frances , Knapper, Steven , Yap, Christina
Blood | August 9, 2017 | Volume: 130 | Issue: 17 | Pages: 1889-1897
Key Points After hydroxycarbamide therapy in high-risk ET, ruxolitinib showed no improvement for complete or partial response rates compared with BAT. Ruxolitinib significantly improved some disease-related symptoms, but rates of thrombosis, hemorrhage, or transformation were not different.